Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER-Medicare-linked data resource

Cancer Medicine

Volumn 7, Issue 7, 2018, Pages 3434-3444

  Lam, Clara ^a   Cronin, Kathleen ^a   Ballard, Rachel ^b   Mariotto, Angela ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

cancer specific survival; diabetes; race; SEER

Indexed keywords

AGED; ARTICLE; BLACK PERSON; BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HODGKIN DISEASE; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RECTUM CANCER; STOMACH CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VERY ELDERLY;

EID: 85047517110     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1554     Document Type: Article

References (70)

1. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314:1021-1029.
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
3. Centers for Disease Control and Prevention. Diabetes Public Health Resource website. http://www.cdc.gov/diabetes/statistics/prev/national/figraceethsex.htm. Accessed May 9, 2016.
4. Beckles GL, Chou C. Disparities in the prevalence of diagnosed diabetes – United States, 1999-2002 and 2011-2014. MMWR Morb Mortal Wkly Rep. 2016;65:1265-1269.
5. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 Incidence and Mortality Web-based Report. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2015. www.cdc.gov/uscs.
6. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337.
7. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290-308.
8. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856-862.
9. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679-1687.
10. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365-1374.
11. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-380.
12. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-2083.
13. Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183:1088-1106.
14. Connor AE, Visvanathan K, Baumgartner KB, et al. Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2016;157:167-178.
15. Barone BB, Yeh H-C, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus, a systematic review and meta-analysis. JAMA. 2008;300:2754-2764.
16. Olson SH, Atoria CL, Cote ML, et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:753-760.
17. Waheed S, Azad N, Waheed S, Yeh HC. Racial disparities and colorectal cancer survival in older adults with and without diabetes mellitus. J Gastroenterol Hepatol. 2014;29:1963-1968.
18. Ma Y, Hébert JR, Balasubramanian R, et al. All-cause, cardiovascular, and cancer mortality rates in postmenopausal white, black, Hispanic, and Asian women with and without diabetes in the United States: the Women's Health Initiative, 1993-2009. Am J Epidemiol. 2013;178:1533-1541.
19. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294:1765-1772.
20. Charlot M, Castro-Webb N, Bethea TN, et al. Diabetes and breast cancer mortality in black women. Cancer Causes Control. 2017;28:61-67.
21. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
22. Warren JL, Klabunde CN, Schrage D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV3-IV18.
23. Surveillance, Epidemiology, and End Results Program (SEER), National Cancer Institute. SEER*Stat software, version 8.2.1 [software program]. www.seer.cancer.gov/seerstat. Accessed November 16, 2015.
24. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results – medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174:860-870.
25. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584-590.
26. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
27. Comorbidity SAS Macro (2014 version); Healthcare Delivery Research Program; National Cancer Institute. www.healthcaredelivery.care.gov/seermedicare/considerations/macro-2014.html. Accessed November 16, 2015.
28. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. Incidence of congestive heart failure in type 2 diabetes. Diabetes Care. 2004;27:1879-1884.
29. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
30. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003;14:S65-S70.
31. Li W, Huang E, Gao S. Type 1 diabetes mellitus and cognitive impairments: a systematic review. J Alzheimers Dis. 2017;57:29-36.
32. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
33. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945-1954.
34. Andersson C, van Gaal L, Caterson ID, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012;55:2348-2355.
35. Norgaard ML, Andersen SS, Schramm TK, et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction – a nationwide study. Diabetologia. 2010;53:1612-1619.
36. Mohammedi K, Woodward M, Hirakawa Y, et al. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care. 2016;39:1796-1803.
37. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
38. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433-1437.
39. Megherbi S-E, Milan C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke, data from the European BIOMED Stroke Project. Stroke. 2003;34:688-694.
40. Mantovsky B, Metzger B, Molitch M, Biller J. Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications. 1996;10:228-242.
41. Abbott RD, Donahue RO, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. JAMA. 1987;257:949-952.
42. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102:1584-1598.
43. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. SEER cause-specific death classification. http://seer.cancer.gov/causespecific/. Accessed November 16, 2015.
44. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Cancer Survival Statistics: Cohort Definition Using Diagnosis Year. https://surveillance.cancer.gov/survival/cohort.html. Accessed November 16, 2015.
45. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.
46. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 [article online], 2008. Atlanta, Georgia: Center for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.
47. Keegan THM, Clarke CA, Chang ET, Shema SJ, Glaser SL. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control. 2009;20:1881-1892.
48. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23:991-1008.
49. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res. 2007;174:49-53.
50. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-518.
51. Richardson LE, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48-53.
52. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31-R43.
53. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
54. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8:915-928.
55. Morss AS, Edel ER. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem. 2007;282:14635-14644.
56. Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev. 2009;18:2397-2405.
57. Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. Arch Intern Med. 2005;165:2090-2095.
58. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29:40-46.
59. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coeberg JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;129:1986-1992.
60. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433-440.
61. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexatecytarabine regimen. Cancer. 2004;100:1179-1185.
62. Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med. 1995;99:22-28.
63. Keating NL, Zaslavsky AM, Herrinton LJ, Selby JV, Wolf RE, Ayanian JZ. Quality of diabetes care among cancer survivors with diabetes. Med Care. 2007;45:869-875.
64. Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:913-923.
65. Raebel MA, Ellis JL, Schroeder EB, et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf. 2014;23:699-710.
66. Heisler M, Smith DM, Hayward RA, Krein SL, Kerr EA. Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care. 2003;41:1221-1232.
67. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
68. Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS. Screening mammogram utilization in women with diabetes. Diabetes Care. 2001;24:2049-2053.
69. Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005;43:132-140.
70. Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Med Care. 2016;54:e55-e64.